Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone

Journal of Clinical Pharmacology

Volumn 51, Issue 2, 2011, Pages 271-278

  Sekar, Vanitha ^a   Tomaka, Frank ^a   Lefebvre, Eric ^b   De Pauw, Martine ^c   Vangeneugden, Tony ^c   Van Den Brink, Wim ^d   Hoetelmans, Richard ^c  

^a Tibotec Inc   (United States)

^b Janssen Cilag BV Netherlands   (Netherlands)

^c TIBOTEC BVBA   (Belgium)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

buprenorphine; Darunavir; methadone; naloxone; pharmacokinetic interaction

Indexed keywords

BUPRENORPHINE; DARUNAVIR; METHADONE; NALOXONE; OPIATE; RITONAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG INTERACTION; FEMALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NAUSEA;

ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; DRUG INTERACTIONS; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; MALE; METHADONE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; RITONAVIR; SULFONAMIDES;

EID: 79551714977     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010365558     Document Type: Article

References (32)

1. Sullivan LE, Fiellin DA Hepatitis C and HIV infections: implications for clinical care in injection drug users. Am J Addict. 2004 ; 13: 1-20.
2. Eap CB, Bourquin M., Martin J., et al. Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. Drug Alcohol Depend. 2000 ; 61: 47-54.
3. Orman JS, Keating GM Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence. Drugs. 2009 ; 69: 577-607.
4. Rainey PM HIV drug interactions: the good, the bad, and the other. Ther Drug Monit. 2002 ; 24: 26-31.
5. McCance-Katz EF, Rainey PM, Friedland G., Jatlow P. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin Infect Dis. 2003 ; 37: 476-482.
6. Clarke SM, Mulcahy FM, Tjia J., et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol. 2001 ; 51: 213-217.
7. Clotet B., Bellos N., Molina JM, et al. POWER 1 and 2 study groups. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007 ; 369: 1169-1178.
8. Madruga JV, Berger D., McMurchie M., et al. TITAN study group. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIVinfected patients in TITAN: a randomised controlled phase III trial. Lancet. 2007 ; 370: 49-58.
9. Mills AM, Nelson M., Jayaweera D., et al. Once-daily darunavir/ ritonavir vs lopinavir/ritonavir in treatment-naïve, HIV-1-infected patients: 96-week analysis of ARTEMIS. AIDS. 2009 ; 23: 1679-1688.
10. Tibotec. 2009. PREZISTA™ (darunavir) full prescribing information. http://www.prezista.com/prezista/documents/us-package-insert.pdf. Accessed 12 November 12, 2009.
11. Tibotec. 2009. PREZISTA™ (darunavir). Summary of product characteristics. http://www.emea.europa.eu/humandocs/PDFs/EPAR/prezista/emea- combined-h707en.pdf. Accessed November 12, 2009.
12. Back D., Sekar V., Hoetelmans RMW. Darunavir: pharmacokinetics and drug interactions. Antiviral Ther. 2008 ; 13: 1-13.
13. Symoron© product information, 2001. http://www.epgonline.org/ viewdrug.cfm/drugId/DR000650/language/lg0012/drugName/Symoron. Accessed August 19, 2009.
14. Suboxone© product information revised 2007. http://www.rxlist.com/ suboxone-drug.htm. Accessed May 21, 2009.
15. Uehlinger C., Crettol S., Chassot P., et al. Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients. J Clin Psychopharmacol. 2007 ; 27: 273-278.
16. Weschules DJ, Bain KT, Richeimer S. Actual and potential drug interactions associated with methadone. Pain Med. 2008 ; 9: 315-344.
17. Bouche MP, Michielsen L., Piot M., Timmerman P. Swift and simultaneous determination of darunavir and ritonavir in human plasma using LC-MS/MS. Paper presented at: 17th International Mass Spectrometry Conference ; August 2006 ; Prague, Czech Republic. Abstract TuP-042.
18. AIDS Clinical Trials Group. 2004 Division of AIDS table for grading the severity of adult and pediatric events. http://www.ucdmc.ucdavis.edu/ clinicaltrials/documents/DAIDS-AE-GradingTable-FinalDec2004.pdf. Accessed November 11, 2009.
19. Gossop M. The development of a short opiate withdrawal scale (SOWS): brief report. Addict Behav. 1990 ; 15: 487-490.
20. Franken IH, Hendriksa VM, van den Brink W. Initial validation of two opiate craving questionnaires: the Obsessive Compulsive Drug Use Scale and the Desires for Drug Questionnaire. Addict Behav. 2002 ; 27: 675-685.
21. Sekar V., Lefebvre E., Spinosa-Guzman S., et al. Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women. Antivir Ther. 2008 ; 13: 563-569.
22. McKeage K., Perry CM, Keam SJ Darunavir, a review of its use in the management of HIV infection in adults. Drugs. 2009 ; 69: 477-503.
23. Armstrong SC, Wynn GH, Sandson NB Pharmacokinetic drug interactions of synthetic opiate analgesics. Psychosomatics. 2009 ; 50: 169-176.
24. Kharasch ED, Bedynek PS, Park S., Whittington D., Walker A., Hoffer C. Mechanisms of ritonavir changes in methadone pharmacokinetics and pharmacodynamics, I: evidence against CYP3A mediation of methadone clearance. Clin Pharmacol Ther. 2008 ; 84: 497-505.
25. Kharasch ED, Walker A., Whittington D., Hoffer C., Bedynek PS Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. Drug Alcohol Depend. 2009 ; 101: 158-168.
26. Cao YJ, Smith PF, Wire MB, et al. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects. Pharmacotherapy. 2008 ; 28: 863-874.
27. Hendrix CW, Wakeford J., Wire MB, et al. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects. Pharmacotherapy. 2004 ; 24: 1110-1121.
28. Friedland G., Andrews L., Schreibman T., et al. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS. 2005 ; 19: 1635-1641.
29. Bruce RD, Altice FL, Gourevitch MN, Friedland GL Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr. 2006 ; 41: 563-572.
30. Bruce RD, McCance-Katz E., Kharasch ED, Moody DE, Morse DE Pharmacokinetic interactions between buprenorphine and antiretroviral medications. Clin Infect Dis. 2006 ; 43 (suppl 4). S216 - S223.
31. McCance-Katz EF, Moody DE, Smith PF, et al. Interactions between buprenorphine and antiretrovirals, II: the protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. Clin Infect Dis. 2006 ; 43 (suppl 4). S235 - S246.
32. McCance-Katz EF, Moody DE, Morse GD, et al. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend. 2007 ; 91: 269-278.